• Nenhum resultado encontrado

Concomitant active tuberculosis prolongs survival in non-small cell lung cancer: a study in a tuberculosis-endemic country.

N/A
N/A
Protected

Academic year: 2017

Share "Concomitant active tuberculosis prolongs survival in non-small cell lung cancer: a study in a tuberculosis-endemic country."

Copied!
7
0
0

Texto

Loading

Imagem

Table 3 shows the clinical factors of NSCLC patients with or without active tuberculosis
Figure 1. Kaplan-Meier survival curve of lung cancer patients with and without active tuberculosis (log rank test, p ,0.01)
Table 4. Immunohistochemical marker indices of squamous cell carcinoma with or without active tuberculosis.
Figure 3. Representative image of immunohistochmical stain demonstrating immunological markers with high and low expression respectively for CD3 (A) (B), CXCR3 (C) (D), and FOXP3 (E) (F)

Referências

Documentos relacionados

Survival and prognostic factors in patients with Non-Small Cell Lung Cancer treated in private health care.. Sobrevida e fatores prognósticos em pacientes com câncer de pulmão de

In a previous study of cases of stage I non-small cell lung cancer (NSCLC), we also reported significant gender-related differences in long-term survival, with better rates

cancers are categorized as small cell lung cancer, a subtype with a neuroendocrine phenotype, or non-small cell lung cancer, which comprises adenocarcinoma, squamous cell

Despite the fact that previous studies found a higher prevalence of chromosome abnormalities in patients with primary amenorrhea than in patients with secondary

cancers are categorized as small cell lung cancer, a subtype with a neuroendocrine phenotype, or non-small cell lung cancer, which comprises adenocarcinoma, squamous cell

Lupeportlandol acetate was inactive in cytotoxicity assays in vitro against three human tumor cell lines: MCF-7 (breast cancer), NCI-H460 (non-small cell lung cancer) and SF-268

Objectives: To determine differences in overall survival and quality of life among patients with stage IV non-small cell lung cancer non-metastatic to the brain treated with

Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern